“showed a trend”

This correlation trend was also observed for the functional BCL-2 BH3 profile and CHOP response, in which a high BAD response showed a trend towards high CHOP IC 50 values ( r = 0.595; p = 0.1323) ( Figure 3 E).

ε4 carriers showed a trend toward increased leptomeningeal artery remodeling (mixed‐effects model, p =0.1325, Figure 1A).

Knee state evaluation time showed a trend of reduction from 9.22 to 7.33 minutes ( P = .1335), and resection time from 13.66 to 12.92 minutes ( P = .4372).

A correlation analysis revealed a negative relation between DNA methylation and gene expression levels that showed a trend towards statistical significance ( P- value = 0.1336, S7B Fig ), thus demonstrating that DNA methylation in rhesus CRC affected gene expression levels.

Patients with delayed surgical treatment offered neoadjuvant androgen deprivation therapy showed a trend towards a reduction in positive surgical margins ( p =0.134), N1 disease ( p =0.424) and pathological down-staging (50% patients with pT2 disease).

Patients with overexpression (z-score >2) and/or amplification of group 3 TKs, which varied independent of molecular phenotype, showed a trend of worse median OS (30.91 vs. 59.26 mos., log-rank p = 0.134) and significantly worse median DFS (27.99 vs. 72.34 mos., log-rank p = 0.0391) than those without alteration (S2D Table in S1 File , Fig 2C ).

Also, LV mass showed a trend towards an increase in the DEB1 subgroup compared to DEB2 ( p = 0.134, Figure 1 E).

Patients with irP relapse showed a trend toward a longer duration from the start of ICI administration to the onset of irP than those without irP relapse ( p = 0.135).

While patients with CMV-DNA PCR levels above 468.5 copies/mL showed a trend toward worse outcomes, this association did not reach statistical significance (OR: 2.04, P = .135).

Significant weight loss, defined as at least 10% weight loss within 6 months prior to treatment, showed a trend toward reduced overall survival (HR 2.007; p = 0.136) and progression-free survival (HR 2.849; p = 0.085) ( Table 3 and Table 4 ).

Interestingly, the median PFS of patients receiving 8 mg, 10 mg and 12 mg anlotinib was 3.0 months (95% CI: 1.54–4.46), 6.1 months (95% CI: 3.71–8.49) and 7.8 months (95% CI: 0.00–17.91), respectively, which showed a trend toward statistical significance ( P = 0.136).

In KORA, the regression analyses showed a trend for the presence of one A-allele to lead to an average increase of 0.12 BMI units (95%CI -0.04;0.28; p-value = 0.136) (Table 6 ).

As expected, homozygous GG carriers of rs4444903 showed a trend of increased EGF level compared with AA carriers ( Fig. 2A, T -test P = 0.136).

Not surprisingly however, Hs 578T was the highest SQLE expresser in our panel, and indeed also SQLE GE levels showed a trend for correlation with terbinafine IC 50 in the six lines panel (ρ = −0.71, P = 0.1361).

Patients with intermediate/high probability of ExPH at ESE showed a trend ( p = 0.137) towards clinical worsening compared to those with low probability of ExPH.

5%; P = 0.002) and showed a trend for improving PFS (3.7 vs. 2.2 months; P = 0.137).

Further, individuals with DCD ( M = 33,782; SD = 6552) showed a trend for decreased tract volume in the right SLF relative to control ( M = 38,444; SD = 6135) ( p = .137).

The time interval between the first ERCP and the CCE showed a trend towards an increased risk of postoperative complications (OR = 1.004, 95% CI 0.999–1.009, p = 0.137).

There was a significant difference in LRFS between patients with resection margins of ≥0–1 mm and >1–5 mm ( p = 0.07), and this difference showed a trend when adjuvant radiotherapy was applied ( p = 0.137).

In addition, we observed an increase in ABCD1 abundance in control hiPSC‐derived astrocytes incubated with C26:0, whereas hiPSC‐derived astrocytes incubated with C26:1 showed a trend suggesting a decrease ( p = 0.1373, Figure 3B ).

In the same dataset, we found that low LDLR expression showed a trend of worsened prognosis ( P = 0.1376) (Fig. 1H ).

5 a, b), the experimental group administered on day +1 also showed a trend towards clinical worsening (mean clinical score AUC (Null: 21.33 ± 15.70, n = 6; sIL21R: 35.70 ± 13.03, n = 7; p = 0.138), weight change AUC (Null: 142.10 ± 79.28, n = 6; sIL21R: 25.89 ± 139.00, n = 7; p = 0.099)) (Fig. 5 c, d).

The generalized HCR group showed a trend toward lower cumulative MACCE rates than did the OPCABG group (9.9% vs. 16.2%; HR, 0.567; 95% CL, 0.268–1.201; P = 0.138), but the differences were not statistically significant.

HER2 positivity showed a trend toward improved OS on multivariable analysis (HR 0.68, 95% CI 0.40–1.13; p = 0.138), though this did not retain statistical significance, likely due to the limited number of HER2-positive patients (n = 23).

Kaplan–Meier analysis showed that among grade IV gliomas (n = 55), patients with higher PNI (>44) showed a trend of OS benefit (p = 0.138).